Biogen Idec creates new standards of care in therapeutic areas with high unmet medical needs. Founded in 1978, Biogen Idec is a global leader in the discovery, development, manufacturing, and commercialization of innovative therapies. Patients in more than 90 countries benefit from Biogen Idec’s significant products that address diseases such as lymphoma, multiple sclerosis, and rheumatoid arthritis.


James Mullen (President, CEO)

Cecil Picket (President, R&d)

Paul Clancy (Executive VP, CFO)

Lawrence Best (Board Member)

Marjin Dekkers (Board Member)

View more details about all 7 people at Biogen Idec